Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Emicizumab Prophylaxis Impact on Health and Joint Outcomes in Hemophilia A
NCT05181618Phase 4Active, not recruiting
- Sponsor
- Roche
- Start
- Jun 2022
- Primary completion
- Nov 2026
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 12
01
Overview
Phase 4, open-label trial of emicizumab in hemophilia A (3 cohorts), sponsored by Roche. Primary endpoints: Haemophilia Early Arthropathy Detection with Ultrasound Score at 36 months, Hemophilia Joint Health Score at 36 months and 9 more. Started Jun 2022; status: active, not recruiting.
02
Drugs
emicizumab
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NCT05181618.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05181618.